Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidates

Panorama of a city business district with office buildings and skyscrapers and superimposed data, charts and diagrams related to stock market, currency exchange and global finance. Blue line graphs with numbers and exchange rates, candlestick charts and financial figures fill the image with a glowing light. Sunset light.

Shares of Cocrystal Pharma Inc.

more than doubled on massive record volume in afternoon trading Tuesday, a day after the biotechnology company said it has made “progress” in developing antiviral drug candidates that target coronaviruses, including those that cause COVID-19. Trading volume skyrocketed to 559.5 million shares, compared with the full-day average of about 832,300 shares. Cocrystal launched its COVID-19 program in March 2020. The stock’s previous record for trading volume was 81.1 million shares on Feb. 24, 2020. “We are aggressively developing novel coronavirus protease inhibitors for COVID-19 prophylactic and therapeutic use,” said President Sam Lee, in Monday release. “Our high-resolution x-ray cocrystal structures further confirmed the specific covalent interaction with this conserved region of the proteases of the coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV viruses.” The stock, which was recently up 104.0%, has now run up 86.0% year to date, while the iShares Nasdaq Biotechnology ETF

has slipped 1.2% and the S&P 500

has gained 10.5%.

Apple Stock Is Sliding. Here’s What Investors Are Worried About.

Previous article

Biden Tax Rule Would Rip Billions From Big Fortunes at Death

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News